Withdraws Guidance with New Product
Announcement
MENLO
PARK, Calif., Oct. 25,
2022 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced
today that it will hold its quarterly conference call to discuss
its third quarter 2022 financial results on Monday, Nov. 7, 2022, at 5:00 p.m. Eastern Time.
PacBio will also host its Inaugural Investor Day on Tuesday, Nov. 15, 2022, at 8:00 a.m. Eastern Time. The event will feature
presentations by members of PacBio's executive team and include
Q&A sessions.
Both events will be webcast live and may be accessed at PacBio's
website at: https://investor.pacificbiosciences.com/.
Third Quarter Earnings
Details
Date: Monday, Nov. 7, 2022 at
5:00 p.m. ET (2:00 p.m. PT)
Listen live via internet or replay:
https://investor.pacificbiosciences.com/
Toll-free: 866-652-5200
International: 412-317-6060
If using the dial-in option, please dial into the call
five to ten minutes prior to start time using the appropriate
number above and ask to join the "PacBio Q3 Earnings Call."
PacBio 2022 Investor Day
Details
Date: Tuesday, Nov. 15, 2022 at
8:00 a.m. ET (5:00 a.m. PT)
Location: The St. Regis Hotel, Two E 55th Street, New York, NY 10022
Listen via internet or replay:
https://investor.pacificbiosciences.com/
2022 Financial Guidance
In light of forthcoming product announcements, we are
withdrawing all prior financial guidance. We plan to provide
additional information during our third quarter earnings call on
Nov. 7, 2022.
About PacBio
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier
life science technology company that is designing, developing and
manufacturing advanced sequencing solutions to help scientists and
clinical researchers resolve genetically complex problems. Our
products and technology under development stem from two highly
differentiated core technologies focused on accuracy, quality and
completeness which include our existing HiFi long read sequencing
and our emerging SBB™ short read sequencing technologies. Our
products address solutions across a broad set of research
applications including human germline sequencing, plant and animal
sciences, infectious disease and microbiology, oncology, and other
emerging applications. For more information, please visit
www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use
in diagnostic procedures.
Forward-Looking
Statements
This press release may contain "forward-looking statements"
within the meaning of Section 21E of the Securities Exchange Act of
1934, as amended, and the U.S. Private Securities Litigation Reform
Act of 1995, including statements relating to forthcoming product
announcements and plans to provide additional information during
our third quarter earnings call. You should not place undue
reliance on forward-looking statements because they are subject to
assumptions, risks, and uncertainties that could cause actual
outcomes and results to differ materially from currently
anticipated results. Factors that could materially affect
actual results can be found in PacBio's most recent filings with
the Securities and Exchange Commission, including PacBio's most
recent reports on Forms 8-K, 10-K, and 10-Q, and include those
listed under the caption "Risk Factors." These forward-looking
statements are based on current expectations and speak only as of
the date hereof; except as required by law, PacBio disclaims any
obligation to revise or update these forward-looking statements to
reflect events or circumstances in the future, even if new
information becomes available.
Contacts
Investors:
Todd Friedman
650.521.8450
ir@pacb.com
Media:
Lizelda Lopez
pr@pacb.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pacbio-to-report-third-quarter-earnings-on-november-7-and-host-inaugural-investor-day-on-november-15-301659280.html
SOURCE Pacific Biosciences of California, Inc.